Common breast cancer mutation induces multipotency and tumour heterogeneity

Understanding how different cell populations arise within a tumour – so-called tumour heterogeneity – is widely regarded as a major challenge for cancer biology.

Mohamed Bentires-Alj and his group at the FMI have discovered how the most frequent mutation in human breast cancer leads to tumour heterogeneity. The PI3-kinase mutation forces cells back into a dedifferentiated, stem-like state from which tumours containing cells of various lineages can develop. These results have been published in Nature.
Read more

A cure at last? New treatment options for an incurable paediatric leukemia

Researchers from the University Children’s Hospital in Zurich, in collaboration with the Bioinformatics Core Facility of the Swiss Institute of Bioinformatics, analysed the drug activity profiles for patient-derived leukemia xenografts (PDX) of a rare, but fatal pediatric acute lymphoblastic leukemia (ALL).

Read more ...

ELIXIR / SIB Innovation & SME Forum: great occasion to exchange with industry

The ELIXIR / SIB Innovation and SME Forum took place in Basel on 9 June 2015 under the headline 'Data-driven innovation in the pharma and biotech industries'. The Forum was an exceptional occasion to exchange with industry and was organized alongside [BC]2 by SIB and ELIXIR.

Read more ...

Laureates of the SIB Awards 2015

Yesterday, the names of the 3 laureates of the SIB Awards 2015 were announced at the 12th [BC]2 - the Basel Computational Biology Conference.

Read more ...
Page 2 of 4

Press contact

marie dangles
Marie Dangles
Head of Communications

maia berman
Maïa Berman
Communications Manager

sylvie clottu
Sylvie Clottu
Communications Assistant
 

SIB Communications
communication@sib.swiss
+41 21 692 40 46